Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Distinct, non-overlapping gene panels of peripheral blood gene expression predict response to infliximab therapy in rheumatoid arthritis and Crohn's disease

ABSTRACT: We used microarrays to identify markers predicting responder status in infliximab treatment in 19 rheumatoid arthritis and 20 Crohn's disease patients at week 0 and week 2 of treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE42296 | GEO | 2013/06/25

SECONDARY ACCESSION(S): PRJNA179561

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Distinct, non-overlapping gene panels of peripheral blood gene expression predict response to infliximab therapy in rheumatoid arthritis and Crohn's disease

Project description:We used microarrays to identify markers predicting responder status in infliximab treatment in 19 rheumatoid arthritis and 20 Crohn's disease patients at week 0 and week 2 of treatment. Peripheral blood samples were obtained at week 0 and week 2 of inxliximab treatment and global gene expression profiling identified markers of responder status.

2013-06-25 | E-GEOD-42296 | biostudies-arrayexpress

Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease.

Project description: Not available

| S-EPMC4064310 | biostudies-literature

PBMC gene expression from Crohn's disease patients before Infliximab therapy.

Project description:PBMC gene expression from Crohn's disease patients before Infliximab therapy.

| PRJNA421740 | ENA

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

Project description:Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC. Keywords: drug response Twenty-four patients with active UC, refractory to corticosteroids and/or immunosuppression, underwent colonoscopy with biopsies from diseased colon within a week prior to the first intravenous infusion of 5 mg infliximab per kg body weight. Response to infliximab was defined as endoscopic and histologic healing at 4-6 weeks after first infliximab treatment. Six control patients with normal colonoscopy were included. Total RNA was isolated from colonic mucosal biopsies, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.

2010-01-06 | E-GEOD-14580 | biostudies-arrayexpress

Expression data from colonic biopsy samples of infliximab treated UC patients

Project description:A gene expression profiling sub-study was conducted in which colonic biopsy samples were collected for RNA extraction and hybridization to microarrays from 48 patients with UC who were participating in ACT 1, a placebo-controlled study of infliximab. Gene expression profiles from infliximab responders were compared with those of baseline and infliximab non-responder samples. Infliximab had a significant effect on mRNA expression in treatment responders, with both infliximab dose and duration of treatment having an effect. Genes affected are primarily involved with inflammatory response, cell-mediated immune responses, and cell-to-cell signaling. Infliximab non-responders had a molecular phenotype that closely resembled that of untreated patients with UC. Unlike responders, non-responders do not effectively modulate TH1, TH2, and TH17 pathways. Gene expression can differentiate placebo and infliximab responders.

2011-07-22 | GSE23597 | GEO

Microarray predictor of response to infliximab in rheumatoid arthritis (RA) patients

Project description:We sought to find a gene-expression multigene predictor of response to infliximab therapy in Rheumatoid Arthritis patients. Using internal and external cross-validation systems we have built and validated an 8-gene predictor for response to infliximab.

2009-10-02 | GSE12051 | GEO

Gene Expression Profiles Predict Infliximab Treatment Response in Patients with Treatment-Resistant Depression

Project description:To further explore predictors and targets of response to infliximab, differential gene expression was examined at baseline and after 6 and 24 hours and 2 weeks after the first infusion of infliximab in TRD patients who were infliximab responders versus nonresponders, and compared to placebo-treated patients. All subjects were administered either infliximab (5mg/kg, n=30) or placebo (n=30) through an indwelling catheter at the Emory Division of Digestive Diseases at 3 separate time points (baseline, 2 weeks and 6 weeks). Infliximab infusion dosing protocol and scheduling were matched to the standard intravenous induction routine for the treatment of inflammatory bowel disease.

2013-04-01 | GSE45468 | GEO

Expression data from colonic biopsy samples of infliximab treated ulcerative colitis patients

2011-07-21 | E-GEOD-23597 | biostudies-arrayexpress

Gene Expression Profiles Predict Infliximab Treatment Response in Patients with Treatment-Resistant Depression

Project description:To further explore predictors and targets of response to infliximab, differential gene expression was examined at baseline and after 6 and 24 hours and 2 weeks after the first infusion of infliximab in TRD patients who were infliximab responders versus nonresponders, and compared to placebo-treated patients. In a recent clinical trial, the TNF antagonist infliximab was found to reduce depressive symptoms compared to placebo but only in patients with increased inflammation as reflected by a CRP >5 mg/L. To further explore predictors and targets of response to infliximab, differential gene expression was examined at baseline and after 6 and 24 hours and 2 weeks after the first infusion of infliximab in TRD patients who were infliximab responders versus nonresponders, and compared to placebo-treated patients.

2013-04-01 | E-GEOD-45468 | biostudies-arrayexpress

Expression profiling of responsiveness to infliximab in rheumatoid arthritis patients

Project description:Identifying gene expression profiles as predictors of a good vs poor response to a combined infliximab/methotrexate treatment in rheumatoid arthritis patients. Keywords: drug response

2005-11-16 | GSE3592 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data